In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually illness progression or even the members are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit goods within three days just https://brd4-targetedtherapyabbv-35578.full-design.com/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described-74589331